JACKPOT26 phase II: Golidocitinib maintenance after first-line systemic therapy in PTCL

Results from the phase II, open-label, single-arm, multicenter JACKPOT26 trial (NCT06511869), evaluating golidocitinib maintenance in adults with peripheral T‑cell lymphoma (PTCL) who achieved complete response (CR; Cohort 1; n = 30) or partial response (PR; Cohort 2; n = 18) after first-line systemic therapy, were published in Blood Cancer Journal by Wei et al. Enrolled patients were transplant-ineligible or did not have a transplant plan. The primary endpoints were adverse events (AEs) and serious adverse events (SAEs).

Key data: In Cohort 1, median disease-free survival (DFS) was 25.7 months, with 12- and 24-month DFS rates of 82.1% and 74.2%, respectively. In Cohort 2, median progression-free survival (PFS) was 17.4 months, with 12- and 24-month PFS rates of 68.8% and 48.6%, respectively. The CR rate among patients with an initial PR was 50%. With a median follow-up of 30.5 and 28.6 months, the median overall survival (OS) was not reached in either cohort. In the overall cohort, Grade ≥3 treatment-related adverse events (TRAEs) occurred in 72.9% of patients and treatment-related SAEs (TRSAEs) in 29.2%; the most common Grade ≥3 TRAEs were decreased neutrophil count (47.9%), decreased white blood cell count (31.3%), decreased lymphocyte count (14.6%), pneumonia (14.6%), and leukopenia (12.5%). TRAEs led to treatment interruption in 60.4% of patients, dose reduction in 16.7%, and discontinuation in 10.0%, with no fatal TRAEs reported.

Key learning: Golidocitinib maintenance therapy demonstrated a manageable safety profile with encouraging efficacy in patients with PTCL following first-line treatment, supporting its continued evaluation as a maintenance option for transplant-ineligible patients with PTCL.